Literature DB >> 31240437

Relationship between Barrett's esophagus and colonic diseases: a role for colonoscopy in Barrett's surveillance.

Yuji Amano1, Ryotaro Nakahara2, Takafumi Yuki3, Daisuke Murakami2, Tetsuro Ujihara2, Iwaki Tomoyuki2, Ryota Sagami2, Satoshi Suehiro2, Yasushi Katsuyama2, Kenji Hayasaka2, Hideaki Harada2, Yasumasa Tada3, Youichi Miyaoka4, Hirofumi Fujishiro5.   

Abstract

BACKGROUND: Given that risk factors for Barrett's carcinogenesis are predictive, appropriate management and surveillance of Barrett's esophagus (BE) may be provided. The presence of colorectal neoplasms (CRNs) is a possible predictor of the development of BE and the progression to esophageal adenocarcinoma (EAC). We evaluated the relationship between BE or EAC and colonic diseases, including neoplasms and diverticulosis.
METHODS: Patients (N = 5606) who underwent both colonoscopy and esophagogastroduodenoscopy between January 2016 and December 2017 at three institutions were enrolled. The relationships between the presence of colonic diseases and BE or EAC and other clinical or endoscopic predictors of the presence of BE were investigated retrospectively.
RESULTS: The prevalence of BE ≥ 1 cm and ≥ 3 cm in length was 13.0% and 0.52%, respectively. BE was closely related with the presence of colorectal adenoma (48.4% vs. 37.2% in non-BE; P < 0.001), adenocarcinoma (16.6% vs. 8.4%, P < 0.001) and colonic diverticulosis (CD) (34.1% vs. 29.3%, P < 0.001). In patients with long-segment BE, CRNs (79.3%, P < 0.001) and CD (48.2%, P = 0.038) were more common. EAC patients also had a statistically significantly higher incidence of CRNs than non-BE patients (87.5% vs. 45.6%, P = 0.027). Diverticulosis at the distal colon correlated significantly with EAC and BE (50.0%, P = 0.010 and 15.4%, P = 0.024, vs. 12.0% in non-BE). Multivariate analysis showed that CRNs (t = 8.55, P < 0.001), reflux esophagitis (t = 5.26, P < 0.001) and hiatal hernia (t = 11.68, P < 0.001) were predictors of BE.
CONCLUSIONS: The presence of CRNs was strongly associated with BE and EAC. Therefore, colonoscopy may be useful for establishing a strategy for the surveillance of BE.

Entities:  

Keywords:  Barrett’s esophagus; Colonic diverticulosis; Colorectal neoplasms; Esophageal adenocarcinoma; Surveillance

Year:  2019        PMID: 31240437     DOI: 10.1007/s00535-019-01600-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  55 in total

1.  Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.

Authors:  Douglas J Robertson; Heidi Larsson; Søren Friis; Lars Pedersen; John A Baron; Henrik T Sørensen
Journal:  Gastroenterology       Date:  2007-06-20       Impact factor: 22.682

2.  Chronic proton pump inhibitor therapy and the risk of colorectal cancer.

Authors:  Yu-Xiao Yang; Sean Hennessy; Kathleen Propert; Wei-Ting Hwang; Alireza Sedarat; James D Lewis
Journal:  Gastroenterology       Date:  2007-06-20       Impact factor: 22.682

3.  Surveillance of patients with long-segment Barrett's esophagus: A multicenter prospective cohort study in Japan.

Authors:  Nobuyuki Matsuhashi; Eiji Sakai; Ken Ohata; Norihisa Ishimura; Junko Fujisaki; Tomoki Shimizu; Katsunori Iijima; Tomoyuki Koike; Takao Endo; Takefumi Kikuchi; Tatsuya Inayoshi; Yuji Amano; Takahisa Furuta; Ken Haruma; Yoshikazu Kinoshita
Journal:  J Gastroenterol Hepatol       Date:  2017-02       Impact factor: 4.029

4.  Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients.

Authors:  Bhaskar Banerjee; Nicholas J Shaheen; Jessica A Martinez; Chiu-Hsieh Hsu; Eugene Trowers; Blake A Gibson; Gary Della'Zanna; Ellen Richmond; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2016-02-23

5.  Impact of the composition of gastric reflux bile acids on Barrett's oesophagus.

Authors:  Yoshiko Takahashi; Yuji Amano; Takafumi Yuki; Yuko Mishima; Yuji Tamagawa; Goichi Uno; Norihisa Ishimura; Shuichi Sato; Shunji Ishihara; Yoshikazu Kinoshita
Journal:  Dig Liver Dis       Date:  2011-04-03       Impact factor: 4.088

6.  The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis.

Authors:  Tusar K Desai; Kumar Krishnan; Niharika Samala; Jashanpreet Singh; John Cluley; Subaiah Perla; Colin W Howden
Journal:  Gut       Date:  2011-10-13       Impact factor: 23.059

7.  Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.

Authors:  Peter C Konturek; Kazimierz Rembiasz; Grzegorz Burnat; Stanisław J Konturek; Marcin Tusinela; Władysław Bielanski; Jens Rehfeld; Danuta Karcz; Eckhart Hahn
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.199

Review 8.  Endoscopic definition of esophagogastric junction for diagnosis of Barrett's esophagus: importance of systematic education and training.

Authors:  Norihisa Ishimura; Yuji Amano; Yoshikazu Kinoshita
Journal:  Dig Endosc       Date:  2009-10       Impact factor: 7.559

Review 9.  Adiponectin and Intelectin-1: Important Adipokine Players in Obesity-Related Colorectal Carcinogenesis.

Authors:  Keisuke Kawashima; Kenichi Maeda; Chiemi Saigo; Yusuke Kito; Kazuhiro Yoshida; Tamotsu Takeuchi
Journal:  Int J Mol Sci       Date:  2017-04-19       Impact factor: 5.923

10.  Influence of hiatal hernia and male sex on the relationship between alcohol intake and occurrence of Barrett's esophagus.

Authors:  Atsuhiro Masuda; Tsuyoshi Fujita; Manabu Murakami; Yukinao Yamazaki; Masao Kobayashi; Shuichi Terao; Tsuyoshi Sanuki; Akihiko Okada; Masayasu Adachi; Hideyuki Shiomi; Yoshifumi Arisaka; Hiromu Kutsumi; Eiji Umegaki; Takeshi Azuma
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

View more
  1 in total

1.  Association between gastroesophageal reflux disease and colorectal cancer risk: a population-based cohort study.

Authors:  Je-Ming Hu; Jia-Jheng Wu; Chih-Hsiung Hsu; Yong-Chen Chen; Yu-Feng Tian; Pi-Kai Chang; Chao-Yang Chen; Yu-Ching Chou; Chien-An Sun
Journal:  Int J Colorectal Dis       Date:  2021-04-16       Impact factor: 2.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.